Hospital cardiovascular drugs top 10! A close look at the competition pattern of enterprises

In the middle and late 20th century, after the annual sales volume of cardiovascular drugs exceeded that of anti infective drugs, the trend of continuous and stable growth has always appeared At present, the global market of cardiovascular drugs is more than 100 billion US dollars, accounting for 16% - 17% of the global pharmaceutical market In recent years, bad living habits lead to the younger onset of cardiovascular disease It is predicted that by 2030, about 23.6 million people will die of cardiovascular disease According to China cardiovascular disease report 2016, cardiovascular disease is the leading cause of death among Chinese residents, with 290 million people suffering from cardiovascular disease With the advent of aging society, the incidence rate of hypertension, hyperlipidemia and coronary heart disease has been increasing year by year, which has led to the development of this kind of drugs Among the top 500 best-selling drugs in the world's seven drug markets in 2016, the growth of biotechnology drugs has made a rapid progress, exceeding the $156.6 billion mark Chemical drugs are still the mainstream, accounting for 80% of the total 52 of the top 500 best-selling drugs are cardiovascular drugs, ranking second only to anti infective drugs Cardiovascular drugs play an important role in clinical practice in China In 2016, the market scale of cardiovascular drugs in three major end markets and six major markets in China exceeded 200 billion yuan, an increase of about 8% over the previous year There are 10 categories and 141 drugs for cardiovascular system drugs in the 2017 edition of the national medical insurance drug catalogue, an increase of 42.42% over the previous edition According to minenet data, in 2016, the amount of cardiovascular drugs used in public hospitals in key cities in China was 14.438 billion yuan, an increase of 6.97% year on year According to the data of the first three quarters of 2017, it is estimated that the market scale of cardiovascular drugs in public hospitals in key cities in 2017 is 15.5 billion yuan, an increase of 7.36% year on year, accounting for 11.76% of hospital drugs At present, "statins" is leading the way, and the position of cardiovascular drugs in the hospital terminal and retail market is increasingly prominent, with a compound annual growth rate of 13.10% in 2008-2017 There are 176 chemical drugs used in the cardiovascular system of public hospitals in key cities, and the purchase amount of top 10 drugs accounts for 51.49% of cardiovascular system drugs, forming a high concentration Among the top 10 public hospitals in key cities, atorvastatin and rosuvastatin occupy two seats Atorvastatin ranks first, with more than $150 billion in sales since Pfizer's Lipitor (atorvastatin tablets) went public in 1997 In 1999, China's Alec first imitated listing and Lipitor entered China In 2016, the amount of atorvastatin used in public hospitals in key cities in China was 1.283 billion yuan, up 8.49% year on year According to the data of the first three quarters of 2017, the amount of atorvastatin used in the sample hospital in 2017 was 1.5 billion yuan, an increase of 16.96% year on year Among them, Pfizer's Lipitor accounts for 77.37%, Beijing Jialin's Arle accounts for 16.99%, Tianfang's Youjia accounts for 4.22%, Zhejiang xindonggang and Guangdong encyclopedia account for 1.42% Rosuvastatin is a rising star, ranking fifth Rosuvastatin was approved by FDA in 2003 In 2006, rosuvastatin (Keding) from AstraZeneca entered the Chinese market, and 6 domestic preparations have been listed so far In 2016, the amount of rosuvastatin used in public hospitals in key cities in China was 646 million yuan, up 10.23% year on year According to the data of the first three quarters of 2017, the annual amount of rosuvastatin used in sample hospitals was 723 million yuan, an increase of 11.81% year on year Among them, AstraZeneca accounted for 69.12%, lunanbeite for 16.63%, JINGNUO for Zhejiang Jingxin for 7.53%, Toto for Zhengda Tianqing for 5.27%, Nanjing Xiansheng, Zhejiang Haizheng and Hainan general Sanyo for 1.45% Among the top 10 cardiovascular drugs, alprostadil, creatine phosphate and complex coenzyme are used for heart disease, and these varieties are weak under the hospital drug control policy In 2016, the amount of alprostadil used in public hospitals in key cities in China was 1.376 billion yuan, up 7.58% year on year; creatine phosphate was 1.261 billion yuan, the same as the previous year; complex coenzyme was 802 million yuan, up 2.82% year on year According to the data of the first three quarters of 2017, the amount of alprostadil used in sample hospitals in the whole year was 1.339 billion yuan, a slight decline; phosphocreatine was 1.275 billion yuan, a year-on-year increase of 1.17%; complex coenzyme was 730 million yuan, a year-on-year decrease of 8.99% Among the six leading enterprises in the market, Beijing Taide accounts for 39.76%, Harbin Pharmaceutical Biology accounts for 16.62%, Chongqing Yaoyou accounts for 15.27%, Benxi Hengkang accounts for 12.97%, Xi'an Libang accounts for 8.78% and Penglai nuokan accounts for 5.62% The market of creatine phosphate is tripartite, with Jilin Yinglian accounting for 35.74%, Harbin laibotong accounting for 27.68%, Haikou Qili accounting for 27.42% and others only accounting for 9.16% The compound coenzyme was exclusively controlled by Beijing Shuanglu Among the top 10 cardiovascular drugs in China's exclusive sample hospitals, peripheral vasodilators account for two seats Butylphthalide is the exclusive product of enpipu pharmaceutical industry of petro group In 2016, the amount of drug used in sample hospitals exceeded 600 million yuan According to the company's financial report, in 2016, the total sales volume of butylphthalide reached 2.926 billion yuan According to the data of the first three quarters of 2017, the amount of butylphthalide used in public hospitals in key cities was 725 million yuan, an increase rate of 20.87% It is conservatively estimated that the total sales volume of butylphthalide in 2017 will exceed 3.5 billion yuan The other is guipaizite injection developed and listed in the Fourth Ring Road of Beijing In 2016, the amount of drug used in sample hospitals was 437 million yuan According to the data of the first three quarters of 2017, the annual drug use amount is 428 million yuan, a slight decline of 1.99% Among them, Beijing Fourth Ring Road accounted for 93.58%, Qilu pharmaceutical accounted for 3.83%, and Fujian Jinshan bio industry accounted for 2.59% Among the top 10 cardiovascular drugs in the leading sample hospitals in the original research of antihypertensive drugs, there are three varieties of antihypertensive drugs In 2016, the amount of calcium antagonists amlodipine and nifedipine used in domestic sample hospitals was RMB 484 million and RMB 378 million respectively; the amount of valsartan, renin-1 inhibitor, was RMB 343 million According to the data of the first three quarters of 2017, the amount of amlodipine used in the whole year is 520 million yuan, with an increase rate of 7.5%; nifedipine is 393 million yuan, with an increase rate of 3.8%; valsartan is 347 million yuan, with an increase rate of 1.06% Among the three drugs, amlodipine accounted for 86.95% of Pfizer, while 28 drugs, such as Cr Secco and Yangzi River Shanghai haini, accounted for only 13.05% Nifedipine, another calcium antagonist, accounted for 92.08% in Bayer, Germany, and only 7.92% in 39 countries such as Shanghai Hyundai and Qingdao Yellow Sea In valsartan, a renin inhibitor, Novartis in Switzerland accounted for 89.73%, while 12 drugs, such as lunambert and Changzhou four drugs, accounted for 10.27% In addition, L-amlodipine is also a rapidly growing domestic drug In 2016, the amount of L-amlodipine used in domestic sample hospitals was nearly 300 million yuan, while in 2016, the amount of domestic L-amlodipine (calculated at retail price) was 4.979 billion yuan Shi Huida, the original research brand drug, has spent more than 3 billion yuan, an increase of 18.15% over the previous year; Xuanning of Shiyao group is 1.122 billion yuan It is estimated that the total market of L-amlodipine in 2017 was 5.542 billion yuan, an increase of 11.31% over the previous year.